INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institutua
![Foto de INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA](/img/noimage.png)
![Foto de University of Washington](/img/noimage_org.png)
University of Washington
Seattle, Estados UnidosUniversity of Washington-ko ikertzaileekin lankidetzan egindako argitalpenak (49)
2024
-
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: A prospective study
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 1
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Blood cancer discovery, Vol. 4, Núm. 2, pp. 150-169
-
Profiling the immune landscape in mucinous ovarian carcinoma
Gynecologic Oncology, Vol. 168, pp. 23-31
-
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials
Seminars in Hematology
-
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222
2022
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
-
Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Journal of Clinical Oncology
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
Prognostic gene expression signature for high-grade serous ovarian cancer
Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250
2019
-
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 394, Núm. 10193, pp. 121-130
-
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
The Lancet, Vol. 394, Núm. 10193, pp. 131-138
-
Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨
Journal of Clinical Oncology
2018
-
Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204
-
Rituximab plus lenalidomide in advanced untreated follicular lymphoma
New England Journal of Medicine, Vol. 379, Núm. 10, pp. 934-946
2017
-
Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci
Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004
-
Rivaroxaban with or without aspirin in stable cardiovascular disease
New England Journal of Medicine, Vol. 377, Núm. 14, pp. 1319-1330
-
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Hematological Oncology